Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice

Abstract

1Muraglitazar, a novel dual (␣/␥) peroxisome proliferatoractivated receptor (PPAR) activator, was investigated for its antidiabetic properties and its effects on metabolic abnormalities in genetically obese diabetic db/db mice. In db/db mice and normal mice, muraglitazar treatment modulates the expression of PPAR target genes in white adipose tissue and liver. In young hyperglycemic db/db mice, muraglitazar treatment (0.03-50 mg ⅐ kg ؊1 ⅐ day ؊1 for 2 weeks) results in dose-dependent reductions of glucose, insulin, triglycerides, free fatty acids, and cholesterol. In older hyperglycemic db/db mice, longer-term muraglitazar treatment (30 mg ⅐ kg ؊1 ⅐ day ؊1 for 4 weeks) prevents time-dependent deterioration of glycemic control and development of insulin deficiency. In severely hyperglycemic db/db mice, muraglitazar treatment (10 mg ⅐ kg ؊1 ⅐ day ؊1 for 2 weeks) improves oral glucose tolerance and reduces plasma glucose and insulin levels. In addition, treatment increases insulin content in the pancreas. Finally, muraglitazar treatment increases abnormally low plasma adiponectin levels, increases high-molecular weight adiponectin complex levels, reduces elevated plasma corticosterone levels, and lowers elevated liver lipid content in db/db mice. The overall conclusions are that in db/db mice, the novel dual (␣/␥) PPAR activator muraglitazar 1) exerts potent and efficacious antidiabetic effects, 2) preserves pancreatic insulin content, and 3) improves metabolic abnormalities such as hyperlipidemia, fatty liver, low adiponectin levels, and elevated corticosterone levels.

Tesaglitazar, a Dual Peroxisome Proliferator- Activated Receptor Agonist (PPARα/γ), Improves Metabolic Abnormalities and Reduces Renal Injury in Obese Zucker Rats

“…Beneficial metabolic effects of glitazars have been demonstrated in animal studies [9,10,12,26,27,28]. …”

Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: Preclinical efficacy and safety in db/db mice

“…It has been postulated that the trend towards increasing weight gain with TZD's treatment is probably due to either adipogenesis or increased plasma volume or both (Harrity et al, 2006). Rosiglitazone at its therapeutic dose shows a significant increase in plasma volume and subsequent decrease in haematocrit and haemoglobin as a result of increased sodium reabsorption in the collecting ducts of kidney (Arakawa et al, 2004).…”

The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice

“…Insulin levels were measured by radioimmunoassay. Hepatic triglyceride content was measured by spectrophotometry and expressed as TG mg/g wet liver weight according to published methods (Harrity et al, 2006).…”